77242113PSA3002 Enrolling

Psoriatic Arthritis Study (2 Years)


Treatment: Oral Age: 18+ Years


Who Can Participate?

Adults aged  18 years and above with active PsA may be eligible to participate.

Inclusion Criteria

  • have a diagnosis of PsA for at least 3 months
  • have active PsA as defined by:
    • at least 3 swollen joints and at least 3 tender joints
    • C-reactive protein (CRP) ≥ 0.1 mg/dL
  • have active plaque psoriasis with at least one psoriatic plaque of ≥ 2 cm diameter or nail changes consistent with psoriasis

Participant Information

  • Participate and receive study treatment at no cost
  • Regular visits with study doctors who specialise in treating psoriatic arthritis (19 visits)
  • Will receive an investigative oral treatment (study drug) or a placebo
  • Reimbursement for study-related expenses may be provided

How Long Will The Study Last?

  • 2 years

Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: May 14, 2025

Official Title

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced Participants With Active Psoriatic Arthritis

ClinicalTrials.gov ID

NCT06807424

Sponsor

Janssen Research & Development, LLC

Study Description

  • Brief Summary:

    The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

  • Condition or Disease:

    Arthritis, Psoriatic

  • Intervention/Treatment:

    Drug: Icotrokinra Drug: Icotrokinra Drug: Icotrokinra,Drug: Placebo
  • Phase:

    PHASE 3

  • Ages Eligible for Study:

    18 Years and older (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL

Inclusion Criteria

  • have a diagnosis of PsA for at least 3 months
  • have active PsA as defined by:
    • at least 3 swollen joints and at least 3 tender joints
    • C-reactive protein (CRP) ≥ 0.1 mg/dL
  • have active plaque psoriasis with at least one psoriatic plaque of ≥ 2 cm diameter or nail changes consistent with psoriasis

Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Psoriatic Arthritis

Psoriatic arthritis is a type of arthritis associated with the skin condition psoriasis. Psoriasis lesions usually appear as dry, red, scaly patches and may occur anywhere on the body. Arthritis causes swelling, pain, stiffness, and tenderness of the joints. Psoriatic arthritis is a persistent condition characterized by inflammation of the skin (psoriasis) and joints (arthritis). Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content